Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
17hon MSN
Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, but don’t call it a failure
Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
17hon MSN
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact
Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback